Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 15/20 | 0.60 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19732730 | 0.87 | RET (0.47) | RETKDRLCKSRCPIK3CD | |
| SCHEMBL19732764 | 0.77 | RET (0.61) | RETBTKKDRLCKSRC | |
| SCHEMBL29780853 | 0.77 | RET (0.47) | RETBTKKDRCYP1A2MAPK1 | |
| SCHEMBL19732703 | 0.76 | RET (1.00) | RETLCKSRC | |
| SCHEMBL19732668 | 0.75 | RET (0.62) | RETBTKKDRLCKSRC | |
| SCHEMBL19732774 | 0.75 | RET (0.62) | RETBTKLCKSRCPIK3CD | |
| SCHEMBL3782852 | 0.73 | RET (0.58) | RETBTKKDRCYP1A2KDM4E | |
| SCHEMBL19732744 | 0.73 | RET (0.59) | RETLCKSRCPIK3CD | |
| SCHEMBL19304024 | 0.72 | EGFR (0.62) | RETKDRCYP1A2MAPK1KDM4E | |
| SCHEMBL29781037 | 0.72 | CYP1A2 (0.64) | RETBTKKDRCYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-01 | — | — | US | disclosed |
| EP-3260454-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-10981920-B2 | — | — | 2021-04-20 | — | — | US | disclosed |
| US-10787457-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| US-20200270261-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20200270260-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| CN-108026101-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-20190092776-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-28 | — | — | US | disclosed |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-10179788-B2 | — | — | 2019-01-15 | — | — | US | disclosed |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3260454-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885BTK 1572/4885KDR 847/4885 |
| US-10179788-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885BTK 2490/4885KDR 709/4885 |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885BTK 1572/4885KDR 847/4885 |
| US-10787457-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885BTK 1572/4885KDR 847/4885 |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885BTK 1572/4885KDR 847/4885 |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885BTK 1572/4885KDR 847/4885 |
| US-20200270260-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885BTK 1572/4885KDR 847/4885 |
| US-10981920-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885BTK 2490/4885KDR 709/4885 |
| US-20200270261-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885BTK 1572/4885KDR 847/4885 |
| US-20190092776-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885BTK 1572/4885KDR 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.